Seattle Genetics has initiated a Phase I clinical trial assessing SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC).
SGN-CD70A is a new antibody-drug conjugate (ADC) targeted to CD70 using Seattle’s new ADC technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open-label, multicentre, dose-escalation Phase I trial is designed to assess the safety and anti-tumour activity of SGN-CD70A.
The primary endpoints of the trial are to estimate the maximum tolerated dose and assess the safety of SGN-CD70A.
Furthermore, the trial will evaluate the anti-tumour activity and pharmacokinetics in patients with CD70-positive metastatic RCC or relapsed or refractory NHL, including mantle cell lymphoma and diffuse large B-cell lymphoma.
Around 95 patients at multiple centres in the US will be enrolled in the trial, which is designed to assess SGN-CD70A administered every three weeks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSeattle Genetics R&D chief medical officer and executive vice-president Jonathan Drachman said: "CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has minimal expression in healthy tissues.
"We are building on the single-agent activity we observed with our former SGN-75 candidate and have designed SGN-CD70A with a goal to have enhanced activity by utilising our next-generation ADC technology.
"Our preclinical data demonstrate that this novel ADC is extremely potent in RCC and NHL models, and we are enthusiastic about commencing a clinical trial of SGN-CD70A in patients with a clear need for new therapeutic options."
Seattle Genetics had previously observed single-agent activity including objective responses in a Phase I clinical trial with an initial CD70-targeted ADC called SGN-75, but did not observe enough activity to support further clinical development.
The company developed a next-generation anti-CD70 ADC using new technology that includes a highly potent cytotoxic agent, called a pyrrolobenzodiazepine (PBD) dimer, stably linked to a CD70-directed antibody via proprietary site-specific conjugation technology.
Image: Micrograph of mantle cell lymphoma, a type of non-Hodgkin lymphoma. Photo: courtesy of Nephron.
